Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda
Standard
Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda. / Sebode, Marcial; Hartl, Johannes; Vergani, Diego; Lohse, Ansgar W; International Autoimmune Hepatitis Group (IAIHG).
In: LIVER INT, Vol. 38, No. 1, 01.2018, p. 15-22.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda
AU - Sebode, Marcial
AU - Hartl, Johannes
AU - Vergani, Diego
AU - Lohse, Ansgar W
AU - International Autoimmune Hepatitis Group (IAIHG)
N1 - © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2018/1
Y1 - 2018/1
N2 - Autoimmune hepatitis is a chronic inflammatory liver disease. Unknown triggers lead to a mainly T cell-mediated immune response targeting the liver, the main auto-antigen of which has not been identified yet. The diagnosis of autoimmune hepatitis is based on the elevation of immunoglobulin G/hypergammaglobulinemia, detection of characteristic autoantibodies as well as a typical pattern on liver histology. Exclusion of other causes of hepatitis and response to immunosuppressive treatment support the diagnosis of autoimmune hepatitis. The mainstay of autoimmune hepatitis treatment has, from its first description to the current time, consisted of predniso(lo)ne to induce remission, in combination with azathioprine, which is used to maintain it. Nonetheless, side effects and non-response with ongoing inflammation despite standard therapy demand treatment alternatives. Only through a better understanding of the pathogenesis of autoimmune hepatitis can a more selective and effective treatment be offered to patients in the future. Until this goal is reached, improvement of diagnostic approaches and optimization of current therapy rank highest on the research agenda for autoimmune hepatitis.
AB - Autoimmune hepatitis is a chronic inflammatory liver disease. Unknown triggers lead to a mainly T cell-mediated immune response targeting the liver, the main auto-antigen of which has not been identified yet. The diagnosis of autoimmune hepatitis is based on the elevation of immunoglobulin G/hypergammaglobulinemia, detection of characteristic autoantibodies as well as a typical pattern on liver histology. Exclusion of other causes of hepatitis and response to immunosuppressive treatment support the diagnosis of autoimmune hepatitis. The mainstay of autoimmune hepatitis treatment has, from its first description to the current time, consisted of predniso(lo)ne to induce remission, in combination with azathioprine, which is used to maintain it. Nonetheless, side effects and non-response with ongoing inflammation despite standard therapy demand treatment alternatives. Only through a better understanding of the pathogenesis of autoimmune hepatitis can a more selective and effective treatment be offered to patients in the future. Until this goal is reached, improvement of diagnostic approaches and optimization of current therapy rank highest on the research agenda for autoimmune hepatitis.
KW - Journal Article
KW - Review
U2 - 10.1111/liv.13458
DO - 10.1111/liv.13458
M3 - SCORING: Review article
C2 - 28432836
VL - 38
SP - 15
EP - 22
JO - LIVER INT
JF - LIVER INT
SN - 1478-3223
IS - 1
ER -
